(Q24203643)

2

0 references

Qi Yuan Yuan

3

0 references

Jun Li

4

0 references

Rong Le Zhou

5

0 references

Guan J Liu

Cochrane Database of Systematic Reviews

6

0 references

publication date

15 February 2012

0 references

published in

0 references

cites work

Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

[Effect of pentoxifylline on the evolution of diabetic nephropathy].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Albuminuria: a target for treatment of type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Trials to assess equivalence: the importance of rigorous methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Slowing the progression of diabetic nephropathy and its cardiovascular consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

The unrecognized prevalence of chronic kidney disease in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

How to protect the kidney in diabetic patients: with special reference to IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

The role of inflammatory cytokines in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Pathogenic perspectives for the role of inflammation in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Protein restriction for diabetic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Are randomized control trial outcomes influenced by the inclusion of a placebo group?: a systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Antihypertensive agents for preventing diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

The importance of placebo effects in pain treatment and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

The effects of spironolactone on nephron function in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Placebo response in studies of major depression: variable, substantial, and growing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Pentoxifylline for diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021

Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021

Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021

Pentoxifylline in management of proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021

Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021

Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021

Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006800.PUB2

7 January 2021